Plasma Fractionation Market : Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015-2020 and Forecast 2021-2027

$ PRICE - $ 3,000.00$ 8,900.00

Plasma Fractionation Market: By Product Type (Albumin, Immunoglobulin, Coagulation Factor Concentrates, Protease Inhibitors and Other Plasma Fractionation Products), By Application (Neurology, Haematology, Immunology, Rheumatology, Haemato-oncology, Critical Care, Pulmonology and Others), By End Users (Hospitals, Clinics, Academic Institutes and Clinical Research Laboratories) and Geography  

 

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global plasma fractionation market size valued at USD 22.8 billion in 2020 and expected to reach USD 36.02 billion by 2027, at a CAGR of 5.56% during the forecast period 2021 to 2027. Plasma fractionation refers to the process of separation, extraction, and purification of plasma. Human plasma contains the large variety of proteins, however, only a few of these proteins are help in producing therapeutic plasma products. Plasma is used in prevention and treatment of various life threatening diseases caused by trauma, immunologic disorders, and infections. Plasma fractionation process is majorly used in treating protein deficiency condition in healthcare applications. The proteins extracted from the plasma are majorly categorized into three main classes: immunoglobulins which are useful in treatment of autoimmune disorders and increasing the immune response of the body, clotting factors which are help in treatment of blood disorders such as haemophilia, and the albumins which are useful in conditions of decreased albumin levels or during fluid loss. Plasma fractionation process is carried by different criteria such as solubility of the products, and their physical and chemical conditions such as ionic strengths, pH levels, and temperature, etc. The removal or inactivation of viruses and prions is an important function of plasma fractionation, and it can be carried by various mechanical and physical treatments for virus inactivation such as nano filtration, detergent/solvent treatment, heat treatment, chromatography centrifugation, ultrafiltration, and sterile filtration in order to achieve homogeneity of plasma, and reduce the risks of viral transmissions. Several international players are actively involved in the development of global plasma fractionation products. In 2015, immunoglobulins commanded for the largest share of the global plasma fractionation market due to rise in prevalence and incidence autoimmune disorders (according to International Journal of Celiac Disease, 2015 the world prevalence and incidence of Autoimmune Diseases are increasing, the global net percent increased per year prevalence and incidence of autoimmune disorders were 12.5±7.9 and 19.1±43.1 respectively). However, the protease inhibitors are expected to highest growth in the forecasting period, due to increasing use of proteases for respiratory diseases and growing application in various diseases. Partnerships, agreements, new products launch, collaborations, acquisitions and mergers, joint ventures, are being adopted by various key players in the global plasma fractionation market. For instance, in 2003, Probitas Pharma acquired Alpha Therapeutic from Mitsubishi Pharma, similarly, Octapharma acquired Mexican fractionator Probifasa S.A. de C.V. for developing the plasma products.

Plasma Fractionation Market

MARKET SUMMARY
-
5.56% CAGR
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 5.56%
  • Largest Market– North America
  • Fastest Growing Market– Asia-Pacific

Plasma Fractionation Market

  • The report on global plasma fractionation market gives historical, current and future market sizes (US$ Bn) based on product type, by application, end users and geographic regions.
  • plasma fractionation market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Grifols S.A
  • CSL Ltd.
  • Shire
  • Octapharma AG
  • Kedrion S.p.A
  • Biotest AG
  • LFB S.A
  • Sanquin
Plasma Fractionation Market

Drivers And Restraints

Plasma fractionation market expected to grow at significant rate over the forecast period due to rise in the incidence of immune and bleeding disorders, increase in the use of alpha-1 antitrypsin and immunoglobulin, rise in prevalence of Alpha-1 Antitrypsin Deficiency (AATD), emphysema, and haemophilia. In addition, development in plasma techniques and plasma utilization are the key factors expected to boost the plasma fractionation market. However, high cost for the plasma products, adverse effects associated with the plasma fractionation products, lack of reimbursement policies, stringent regulatory policies, and increase in the recombinant coagulation factors might hinder the growth of plasma fractionation market over the forecast timeframe.


North-America got significant share

Plasma Fractionation Market

Geographically, global plasma fractionation market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the global plasma fractionation market followed by Europe and Asia-Pacific. The largest share of North-America in global plasma fractionation market is due to increasing use of immunoglobulins in neurological diseases and increasing use of prophylaxis treatments for chronic diseases in this region (According to Centres of Disease Control (CDC), in 2012, chronic diseases were one of the leading causes of death and disability in the U.S., with an estimated 117 Mn adults suffering from some form of chronic disease). Europe is the second largest region for global plasma fractionation market due to the rise in aging population and increase in the prevalence of chronic diseases. However, Asia-Pacific is expected to register significant growth rate over the forecast owing to the increasing aging population, growing using of albumin and immunoglobulin, and an increasing focus on better diagnosis, prophylactic treatments, medical research, and organ transplantations in Asia-Pacific regions.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Notable Market Developments

  • In 2017, Grifols opens new lines of research with the acquisition of a 44% stake in GigaGen for US$ 35Mn
  • In 2015, Baxalta receives CHMP positive opinion for sanquin to begin production, purification and enhancing global supply of plasma based therapies
  • In 2014, CSL Behring launched US$ 450 Mn capacity expansion to meet growing need for life-saving, and life improving therapies in plasma fractionation

Key

Report Outline

Plasma Fractionation Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content

1. Executive summary

2. Global Plasma Fractionation Market Introduction

      2.1. Global Plasma Fractionation Market – Taxonomy
      2.2. Global Plasma Fractionation Market – Definitions
            2.2.1. Product Type

            2.2.2. End User

3. Global Plasma Fractionation Market Dynamics

      3.1. Drivers
      3.2. Restraints
      3.3. Opportunities/Unmet Needs of the Market
      3.4. Trends
      3.5. Global Plasma Fractionation Market Dynamics – Factors Impact Analysis
      3.6. Global Plasma Fractionation Market– Regulations
            3.6.1. U.S
            3.6.2. Europe

            3.6.3. Japan

4. Global Plasma Fractionation Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026

      4.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

      4.3. Market Oppurtunity Analysis

5. Global Plasma Fractionation Market, By Product Type, 2015 – 2019 and Forecast, 2020 – 2026

      5.1. Albumin
            5.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            5.1.3. Market Opportunity Analysis
      5.2. Immunoglobulins
            5.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            5.2.3. Market Opportunity Analysis
      5.3. Coagulation factor concentrates
            5.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            5.3.3. Market Opportunity Analysis
      5.4. Protease inhibitors
            5.4.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            5.4.3. Market Opportunity Analysis
      5.5. Other Plasma Fractionation Products
            5.5.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

            5.5.3. Market Opportunity Analysis

6. Global Plasma Fractionation Market Forecast, By Application, 2015 – 2019 and Forecast, 2020 – 2026

      6.1. Neurology
            6.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            6.1.3. Market Opportunity Analysis
      6.2. Hematology
            6.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            6.2.3. Market Opportunity Analysis
      6.3. Immunology
            6.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            6.3.3. Market Opportunity Analysis
      6.4. Rheumatology
            6.4.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            6.4.3. Market Opportunity Analysis
      6.5. Haemato-oncology
            6.5.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            6.5.3. Market Opportunity Analysis
      6.6. Critical Care
            6.6.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            6.6.3. Market Opportunity Analysis
      6.7. Pulmonology
            6.7.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            6.7.3. Market Opportunity Analysis
      6.8. Others
            6.8.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

            6.8.3. Market Opportunity Analysis

7. Global Plasma Fractionation Market Forecast, By End user, 2015 – 2019 and Forecast, 2020 – 2026

      7.1. Hospitals
            7.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            7.1.3. Market Opportunity Analysis
      7.2. Clinics
            7.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            7.2.3. Market Opportunity Analysis
      7.3. Academic Institutes
            7.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            7.3.3. Market Opportunity Analysis
      7.4. Clinical Research Laboratories
            7.4.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

            7.4.3. Market Opportunity Analysis

8. Global Plasma Fractionation Market Forecast, By Region, 2015 – 2019 and Forecast, 2020 – 2026

      8.1. North America
            8.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            8.1.3. Market Opportunity Analysis
      8.2. Europe
            8.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            8.2.3. Market Opportunity Analysis
      8.3. Asia-Pacific
            8.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            8.3.3. Market Opportunity Analysis
      8.4. Latin America
            8.4.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            8.4.3. Market Opportunity Analysis
      8.5. Middle East and Africa
            8.5.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
            8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
            8.5.3. Market Opportunity Analysis

      8.6. Global Plasma Fractionation Market- Opportunity Analysis Index – By Product Type, By Application, By End user, and Region, 2020 – 2026

9. North America Plasma Fractionation Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026

      9.1. Product Type Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
            9.1.1. Albumin
            9.1.2. Immunoglobulin
                    9.1.2.1. Intravenous immunoglobulin
                    9.1.2.2. Subcutaneous immunoglobulin
                    9.1.2.3. Others
            9.1.3. Coagulation Factor Concentrates
                    9.1.3.1. Factor viii
                    9.1.3.2. Factor ix
                    9.1.3.3. Factor xiii
                    9.1.3.4. Prothrombin complex concentrates
                    9.1.3.5. Von Willebrand factor (VWF)
            9.1.4. Protease Inhibitors
            9.1.5. Other Plasma Fractionation Products
      9.2. Application Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
            9.2.1. Neurology
            9.2.2. Hematology
            9.2.3. Immunology
            9.2.4. Rheumatology
            9.2.5. Haemato-oncology
            9.2.6. Critical Care
            9.2.7. Pulmonology
            9.2.8. Others
      9.3. End user Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
            9.3.1. Hospitals
            9.3.2. Clinics
            9.3.3. Academic Institutes
            9.3.4. Clinical Research Laboratories
      9.4. Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
            9.4.1. U.S.
            9.4.2. Canada
      9.5. North America Plasma Fractionation Market- Opportunity Analysis Index – By Product Type, By Application, By End user, and Country, 2020 – 2026

      9.6. North America Plasma Fractionation Market Dynamics – Trends

10. Europe Plasma Fractionation Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026

      10.1. Product Type Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
            10.1.1. Albumin
            10.1.2. Immunoglobulin
                    10.1.2.1. Intravenous immunoglobulin
                    10.1.2.2. Subcutaneous immunoglobulin
                    10.1.2.3. Others
            10.1.3. Coagulation Factor Concentrates
                    10.1.3.1. Factor viii
                    10.1.3.2. Factor ix
                    10.1.3.3. Factor xiii
                    10.1.3.4. Prothrombin complex concentrates
                    10.1.3.5. Von Willebrand factor (VWF)
            10.1.4. Protease Inhibitors
            10.1.5. Other Plasma Fractionation Products
      10.2. Application Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
            10.2.1. Neurology
            10.2.2. Hematology
            10.2.3. Immunology
            10.2.4. Rheumatology
            10.2.5. Haemato-oncology
            10.2.6. Critical Care
            10.2.7. Pulmonology
            10.2.8. Others
      10.3. End user Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
            10.3.1. Hospitals
            10.3.2. Clinics
            10.3.3. Academic Institutes
            10.3.4. Clinical Research Laboratories
      10.4. Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
            10.4.1. Germany
            10.4.2. UK
            10.4.3. France
            10.4.4. Spain
            10.4.5. Italy
            10.4.6. Russia
            10.4.7. Poland
            10.4.8. Rest of Europe
      10.5. Europe Plasma Fractionation Market- Opportunity Analysis Index – By Product Type, By Application, By End user Type, and Country, 2020 – 2026

      10.6. Europe Plasma Fractionation Market Dynamics – Trends

11. Asia-Pacific Plasma Fractionation Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026

      11.1. Product Type Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
            11.1.1. Albumin
            11.1.2. Immunoglobulin
                    11.1.2.1. Intravenous immunoglobulin
                    11.1.2.2. Subcutaneous immunoglobulin
                    11.1.2.3. Others
            11.1.3. Coagulation Factor Concentrates
                    11.1.3.1. Factor viii
                    11.1.3.2. Factor ix
                    11.1.3.3. Factor xiii
                    11.1.3.4. Prothrombin complex concentrates
                    11.1.3.5. Von Willebrand factor (VWF)
            11.1.4. Protease Inhibitors
            11.1.5. Other Plasma Fractionation Products
      11.2. Application Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
            11.2.1. Neurology
            11.2.2. Hematology
            11.2.3. Immunology
            11.2.4. Rheumatology
            11.2.5. Haemato-oncology
            11.2.6. Critical Care
            11.2.7. Pulmonology
            11.2.8. Others
      11.3. End user Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
            11.3.1. Hospitals
            11.3.2. Clinics
            11.3.3. Academic Institutes
            11.3.4. Clinical Research Laboratories
      11.4. Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
            11.4.1. Japan
            11.4.2. China
            11.4.3. India
            11.4.4. ASEAN
            11.4.5. Australia & New Zealand
            11.4.6. Rest of Asia-Pacific
      11.5. Asia-Pacific Plasma Fractionation Market- Opportunity Analysis Index – By Product Type, By Application, By End user Type, and Country, 2020 – 2026

      11.6. Asia-Pacific Plasma Fractionation Market Dynamics – Trends

12. Latin America Plasma Fractionation Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026

      12.1. Product Type Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
            12.1.1. Albumin
            12.1.2. Immunoglobulin
                    12.1.2.1. Intravenous immunoglobulin
                    12.1.2.2. Subcutaneous immunoglobulin
                    12.1.2.3. Others
            12.1.3. Coagulation Factor Concentrates
                    12.1.3.1. Factor viii
                    12.1.3.2. Factor ix
                    12.1.3.3. Factor xiii
                    12.1.3.4. Prothrombin complex concentrates
                    12.1.3.5. Von Willebrand factor (VWF)
            12.1.4. Protease Inhibitors
            12.1.5. Other Plasma Fractionation Products
      12.2. Application Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
            12.2.1. Neurology
            12.2.2. Hematology
            12.2.3. Immunology
            12.2.4. Rheumatology
            12.2.5. Haemato-oncology
            12.2.6. Critical Care
            12.2.7. Pulmonology
            12.2.8. Others
      12.3. End user Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
            12.3.1. Hospitals
            12.3.2. Clinics
            12.3.3. Academic Institutes
            12.3.4. Clinical Research Laboratories
      12.4. Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
            12.4.1. Brazil
            12.4.2. Mexico
            12.4.3. Argentina
            12.4.4. Venezuela
            12.4.5. Rest of Latin America
      12.5. Latin America Plasma Fractionation Market- Opportunity Analysis Index – By Product Type, By Application, By End user Type, and Country, 2020 – 2026

      12.6. Latin America Plasma Fractionation Market Dynamics – Trends

13. Middle East & Africa Plasma Fractionation Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026

      13.1. Product Type Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
            13.1.1. Albumin
            13.1.2. Immunoglobulin
                    13.1.2.1. Intravenous immunoglobulin
                    13.1.2.2. Subcutaneous immunoglobulin
                    13.1.2.3. Others
            13.1.3. Coagulation Factor Concentrates
                    13.1.3.1. Factor viii
                    13.1.3.2. Factor ix
                    13.1.3.3. Factor xiii
                    13.1.3.4. Prothrombin complex concentrates
                    13.1.3.5. Von Willebrand factor (VWF)
            13.1.4. Protease Inhibitors
            13.1.5. Other Plasma Fractionation Products
      13.2. Application Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
            13.2.1. Neurology
            13.2.2. Hematology
            13.2.3. Immunology
            13.2.4. Rheumatology
            13.2.5. Haemato-oncology
            13.2.6. Critical Care
            13.2.7. Pulmonology
            13.2.8. Others
      13.3. End user Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
            13.3.1. Hospitals
            13.3.2. Clinics
            13.3.3. Academic Institutes
            13.3.4. Clinical Research Laboratories
      13.4. Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
            13.4.1. Gulf Cooperation Council (GCC) Countries
            13.4.2. Israel
            13.4.3. South Africa
            13.4.4. Rest of MEA
      13.5. MEA Plasma Fractionation Market- Opportunity Analysis Index – By Product Type, By Application, By End user, and Country, 2020 – 2026

      13.6. MEA Plasma Fractionation Market Dynamics – Trends

14. Competition Landscape

      14.1. Strategic Dashboard of Top Market Players
      14.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
            14.2.1. Grifols S.A (Spain)
            14.2.2. CSL Ltd. (Australia)
            14.2.3. Shire (Ireland)
            14.2.4. Octapharma AG (Switzerland)
            14.2.5. Kedrion S.p.A (Italy)
            14.2.6. China Biologic Products, Inc. (China)
            14.2.7. Biotest AG (OGEL GmbH) (Germany)
            14.2.8. LFB S.A (France)

            14.2.9. Sanquin (Netherlands)

15. Research Methodology

16. Key Assumptions and Acronyms


Report

Company Profile

  • Grifols S.A (Spain)
  • CSL Ltd. (Australia)
  • Shire (Ireland
  • Octapharma AG (Switzerland)
  • Kedrion S.p.A (Italy)
  • China Biologic Products, Inc. (China)
  • Biotest AG (OGEL GmbH) (Germany)
  • LFB S.A (France)
  • Sanquin (Netherlands)

Description

The global plasma fractionation market size valued at USD 22.8 billion in 2020 and expected to reach USD 36.02 billion by 2027, at a CAGR of 5.56% during the forecast period 2021 to 2027. Plasma fractionation refers to the process of separation, extraction, and purification of plasma. Human plasma contains the large variety of proteins, however, only a few of these proteins are help in producing therapeutic plasma products. Plasma is used in prevention and treatment of various life threatening diseases caused by trauma, immunologic disorders, and infections. Plasma fractionation process is majorly used in treating protein deficiency condition in healthcare applications. The proteins extracted from the plasma are majorly categorized into three main classes: immunoglobulins which are useful in treatment of autoimmune disorders and increasing the immune response of the body, clotting factors which are help in treatment of blood disorders such as haemophilia, and the albumins which are useful in conditions of decreased albumin levels or during fluid loss. Plasma fractionation process is carried by different criteria such as solubility of the products, and their physical and chemical conditions such as ionic strengths, pH levels, and temperature, etc. The removal or inactivation of viruses and prions is an important function of plasma fractionation, and it can be carried by various mechanical and physical treatments for virus inactivation such as nano filtration, detergent/solvent treatment, heat treatment, chromatography centrifugation, ultrafiltration, and sterile filtration in order to achieve homogeneity of plasma, and reduce the risks of viral transmissions. Several international players are actively involved in the development of global plasma fractionation products. In 2015, immunoglobulins commanded for the largest share of the global plasma fractionation market due to rise in prevalence and incidence autoimmune disorders (according to International Journal of Celiac Disease, 2015 the world prevalence and incidence of Autoimmune Diseases are increasing, the global net percent increased per year prevalence and incidence of autoimmune disorders were 12.5±7.9 and 19.1±43.1 respectively). However, the protease inhibitors are expected to highest growth in the forecasting period, due to increasing use of proteases for respiratory diseases and growing application in various diseases. Partnerships, agreements, new products launch, collaborations, acquisitions and mergers, joint ventures, are being adopted by various key players in the global plasma fractionation market. For instance, in 2003, Probitas Pharma acquired Alpha Therapeutic from Mitsubishi Pharma, similarly, Octapharma acquired Mexican fractionator Probifasa S.A. de C.V. for developing the plasma products.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX